LPS-induced cortical kynurenic acid and neurogranin (cas 132654-77-4)-NFAT signaling is associated with deficits in stimulus processing during Pavlovian conditioning
-
Add time:08/30/2019 Source:sciencedirect.com
The N-Methyl-d-Aspartate receptor (NMDAR) antagonist kynurenic acid (KYNA) and the post-synaptic calmodulin binding protein neurogranin (Nrgn) have been implicated in neurological and neuropsychiatric conditions including Alzheimer's disease and schizophrenia. This study indicates that systemic dual-lipopolysaccharide (LPS) injections increases KYNA in the medial prefrontal cortex (mPFC), which is accompanied with increased phosphorylation of nuclear factor kappa chain of activated B cells (NFκB) and activation of the nuclear factor of activated T- cells (NFAT). Our results also indicate that dual-LPS increases Nrgn phosphorylation and concomitantly reduces phosphorylation of calmodulin kinase-II (CaMKII). We confirmed that systemic blockade of kynurenine-3 monooxygenase in conjunction with kynurenine administration results in significant increases in Nrgn phosphorylation and a significant reduction of CaMKII phosphorylation in the mPFC. Consequently, dual-LPS administration induced significant impairments in stimulus processing during Pavlovian conditioning. Taken together, our study indicates that elevations in KYNA in the mPFC can directly regulate NMDA-Nrgn-CaMKII signaling, suggesting that neuroinflammatory conditions affecting this pathway may be associated with cognitive dysfunction.
We also recommend Trading Suppliers and Manufacturers of neurogranin (cas 132654-77-4). Pls Click Website Link as below: cas 132654-77-4 suppliers
Prev:Rapid communicationAttenuation of opioid tolerance by antisense oligodeoxynucleotides targeting neurogranin (cas 132654-77-4)
Next:Research Reportneurogranin (cas 132654-77-4) in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research Reportneurogranin (cas 132654-77-4) in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease08/31/2019
- Rapid communicationAttenuation of opioid tolerance by antisense oligodeoxynucleotides targeting neurogranin (cas 132654-77-4)08/29/2019
- neurogranin (cas 132654-77-4) in the nucleus accumbens regulates NMDA receptor tolerance and motivation for ethanol seeking08/28/2019
- Research Reportneurogranin (cas 132654-77-4) binds α-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson’s disease08/27/2019
- Serum neurogranin (cas 132654-77-4) measurement as a biomarker of acute traumatic brain injury08/26/2019
- Featured ArticleC-terminal neurogranin (cas 132654-77-4) is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease08/25/2019
- Effects of myeloid sirtuin 1 deficiency on hypothalamic neurogranin (cas 132654-77-4) in mice fed a high-fat diet08/24/2019
- neurogranin (cas 132654-77-4) regulates sensorimotor gating through cortico-striatal circuitry08/23/2019


